Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward
This paper presents findings of an OECD review of managed entry agreements in OECD countries and EU member states conducted in 2018 and 2019. Findings are based on discussions with the OECD Expert Group on Pharmaceuticals and Medical Devices, responses by experts from 12 OECD countries to a survey a...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2019
|
| Schriftenreihe: | OECD Health Working Papers
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | This paper presents findings of an OECD review of managed entry agreements in OECD countries and EU member states conducted in 2018 and 2019. Findings are based on discussions with the OECD Expert Group on Pharmaceuticals and Medical Devices, responses by experts from 12 OECD countries to a survey and semi-structured interviews, and on the literature as well as information published by national authorities responsible for coverage and pricing of medicines |
| Beschreibung: | 1 Online-Ressource (101 Seiten) |
| DOI: | 10.1787/6e5e4c0f-en |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047933193 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220413s2019 xx o|||| 00||| eng d | ||
| 024 | 7 | |a 10.1787/6e5e4c0f-en |2 doi | |
| 035 | |a (ZDB-13-SOC)06129697X | ||
| 035 | |a (OCoLC)1312689462 | ||
| 035 | |a (DE-599)BVBBV047933193 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Wenzl, Martin |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Performance-based managed entry agreements for new medicines in OECD countries and EU member states |b How they work and possible improvements going forward |c Martin Wenzl and Suzannah Chapman |
| 264 | 1 | |a Paris |b OECD Publishing |c 2019 | |
| 300 | |a 1 Online-Ressource (101 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers | |
| 520 | |a This paper presents findings of an OECD review of managed entry agreements in OECD countries and EU member states conducted in 2018 and 2019. Findings are based on discussions with the OECD Expert Group on Pharmaceuticals and Medical Devices, responses by experts from 12 OECD countries to a survey and semi-structured interviews, and on the literature as well as information published by national authorities responsible for coverage and pricing of medicines | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 650 | 4 | |a European Union | |
| 700 | 1 | |a Chapman, Suzannah |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/6e5e4c0f-en |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033314687 | |
Datensatz im Suchindex
| _version_ | 1818806029381533696 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Wenzl, Martin |
| author2 | Chapman, Suzannah |
| author2_role | ctb |
| author2_variant | s c sc |
| author_facet | Wenzl, Martin Chapman, Suzannah |
| author_role | aut |
| author_sort | Wenzl, Martin |
| author_variant | m w mw |
| building | Verbundindex |
| bvnumber | BV047933193 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)06129697X (OCoLC)1312689462 (DE-599)BVBBV047933193 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/6e5e4c0f-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV047933193</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220413s2019 xx o|||| 00||| eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/6e5e4c0f-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)06129697X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1312689462</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047933193</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wenzl, Martin</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Performance-based managed entry agreements for new medicines in OECD countries and EU member states</subfield><subfield code="b">How they work and possible improvements going forward</subfield><subfield code="c">Martin Wenzl and Suzannah Chapman</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (101 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This paper presents findings of an OECD review of managed entry agreements in OECD countries and EU member states conducted in 2018 and 2019. Findings are based on discussions with the OECD Expert Group on Pharmaceuticals and Medical Devices, responses by experts from 12 OECD countries to a survey and semi-structured interviews, and on the literature as well as information published by national authorities responsible for coverage and pricing of medicines</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">European Union</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chapman, Suzannah</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/6e5e4c0f-en</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033314687</subfield></datafield></record></collection> |
| id | DE-604.BV047933193 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T19:35:00Z |
| indexdate | 2024-12-18T19:03:16Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033314687 |
| oclc_num | 1312689462 |
| open_access_boolean | 1 |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (101 Seiten) |
| psigel | ZDB-13-SOC |
| publishDate | 2019 |
| publishDateSearch | 2019 |
| publishDateSort | 2019 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Wenzl, Martin Verfasser aut Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward Martin Wenzl and Suzannah Chapman Paris OECD Publishing 2019 1 Online-Ressource (101 Seiten) txt rdacontent c rdamedia cr rdacarrier OECD Health Working Papers This paper presents findings of an OECD review of managed entry agreements in OECD countries and EU member states conducted in 2018 and 2019. Findings are based on discussions with the OECD Expert Group on Pharmaceuticals and Medical Devices, responses by experts from 12 OECD countries to a survey and semi-structured interviews, and on the literature as well as information published by national authorities responsible for coverage and pricing of medicines Social Issues/Migration/Health European Union Chapman, Suzannah ctb https://doi.org/10.1787/6e5e4c0f-en Verlag kostenfrei Volltext |
| spellingShingle | Wenzl, Martin Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward Social Issues/Migration/Health European Union |
| title | Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward |
| title_auth | Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward |
| title_exact_search | Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward |
| title_exact_search_txtP | Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward |
| title_full | Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward Martin Wenzl and Suzannah Chapman |
| title_fullStr | Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward Martin Wenzl and Suzannah Chapman |
| title_full_unstemmed | Performance-based managed entry agreements for new medicines in OECD countries and EU member states How they work and possible improvements going forward Martin Wenzl and Suzannah Chapman |
| title_short | Performance-based managed entry agreements for new medicines in OECD countries and EU member states |
| title_sort | performance based managed entry agreements for new medicines in oecd countries and eu member states how they work and possible improvements going forward |
| title_sub | How they work and possible improvements going forward |
| topic | Social Issues/Migration/Health European Union |
| topic_facet | Social Issues/Migration/Health European Union |
| url | https://doi.org/10.1787/6e5e4c0f-en |
| work_keys_str_mv | AT wenzlmartin performancebasedmanagedentryagreementsfornewmedicinesinoecdcountriesandeumemberstateshowtheyworkandpossibleimprovementsgoingforward AT chapmansuzannah performancebasedmanagedentryagreementsfornewmedicinesinoecdcountriesandeumemberstateshowtheyworkandpossibleimprovementsgoingforward |